Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Issue 1 (3rd October 2018) - Jeter, Joanne M.
Abstract : Recent progress in the treatment of advanced melanoma has led to unprecedented improvements in overall survival and, as these new melanoma treatments have been developed and deployed in the clinic, much has been learned about the natural history of the disease. Now is the time to apply that knowledge toward the design and clinical evaluation of new chemoprevention agents. Melanoma chemoprevention has the potential to reduce dramatically both the morbidity and the high costs associated with treating patients who have metastatic disease. In this work, scientific and clinical melanoma experts from the national Melanoma Prevention Working Group, composed of National Cancer Trials Network investigators, discuss research aimed at discovering and developing (or repurposing) drugs and natural products for the prevention of melanoma and propose an updated pipeline for translating the most promising agents into the clinic. The mechanism of action, preclinical data, epidemiological evidence, and results from available clinical trials are discussed for each class of compounds. Selected keratinocyte carcinoma chemoprevention studies also are considered, and a rationale for their inclusion is presented. These data are summarized in a table that lists the type and level of evidence available for each class of agents. Also included in the discussion is an assessment of additional research necessary and the likelihood that a given compound may be a suitable candidate for a phase 3 clinical trial within the next 5 years. Abstract : In this work, experts from the national Melanoma Prevention Working Group, comprised of National Cancer Trials Network participants, discuss mechanisms of action, preclinical data, epidemiologic evidence, and results from available clinical trials for the most promising melanoma chemoprevention agents. The work concludes with an assessment of additional necessary research and the likelihood that a given compound may be a suitable candidate for a phase 3 clinical trial within the next 5 years.